



HealthLinx Limited

## **HEALTHLINX LIMITED**

ACN 098 640 352

("the Company" or "HTX")

21 November 2014

### **GRANT OF EXTENSION OF TIME TO HOLD AGM AND EXECUTION OF TERMS SHEET FOR SALE OF EXISTING INTELLECTUAL PROPERTY PORTFOLIO**

The Company wishes to advise shareholders that, in response to an application submitted by the Company, ASIC has extended the period within which the Company must hold its annual general meeting until 12 January 2015.

The Company sought the extension to allow time for the 2013-2014 audited financial statements to be finalised and to enable the Company to finalise the terms of a proposal for the disposal of its existing intellectual property portfolio (described further below). The extension will enable the Company to incorporate a resolution in the notice of annual general meeting seeking approval for the disposal of its existing intellectual property thereby avoiding the costs and delay of calling and holding a further meeting.

The Company has entered into a Terms Sheet for the sale of its existing intellectual property portfolio, on an 'as is' and 'where is' basis, to Inex Innovations Exchange Pte Ltd (Innovations Exchange). Innovations Exchange is a Singapore based molecular diagnostic company focused on the research, development, marketing and licensing of innovative technology for the advancement of women, maternal and fetal health. The purchase price will be the sum of \$60,000 plus GST. The proposed sale is subject to the following conditions:

- the parties entering into a definitive contract to more fully record the terms of the sale on terms which are consistent with the Terms Sheet;
- the Company obtaining all necessary shareholder and regulatory approvals; and
- Innovations Exchange completing a due diligence investigation into the status of the Company's existing intellectual property portfolio, including enquiries confirming that the portfolio is in good order and is capable of being recommissioned.

As announced on 2 October 2014, the Company has entered into a binding Terms Sheet to acquire Manalto Inc. which owns an emerging social media management software business operating out of the USA. Accordingly, the existing intellectual property is not the main focus of the Company which,

HealthLinx Limited ABN 88 098 640 352

Suite 1, Level 6, 50 Queen Street, Melbourne VIC 3000 Australia

Postal Address: PO Box 16109, Collins Street West VIC 8007 Australia

Telephone: +61 (0)3 8692 9048 Facsimile: +61 (0)3 8692 9040

as part of the process of acquiring Manalto Inc., anticipates seeking shareholder approval to change the nature of its main business from pharmaceuticals and biotechnology to software development and technology. Any such change in activities, and the acquisition of Manalto Inc., will be subject to shareholder approval. As part of the proposed acquisition of Manalto Inc. and the change in the nature and scale of the Company's activities, the Company will be required to re-comply with Chapters 1 and 2 of the Listing Rules as if it were applying for admission to the official list of ASX, as required by ASX Listing Rule 11.1.3.

The Company intends to hold its annual general meeting on 12 January 2015. A notice of annual general meeting, incorporating a resolution seeking approval for the proposed sale to Innovations Exchange, will be dispatched to shareholders shortly.

For and on behalf of the board

A handwritten signature in black ink, consisting of a large, stylized 'Q' followed by a horizontal line and a small upward flick.

Michael Quinert  
Director